Member access

4-Traders Homepage  >  Shares  >  Nyse  >  Johnson & Johnson    JNJ   US4781601046


News SummaryMost relevantAll newsSector news 

Johnson & Johnson : J&J Chairman Weldon's Salary Cut To $1 Million After Stepping Down As CEO

05/07/2012 | 05:51pm US/Eastern
   By Peter Loftus 

Johnson & Johnson (JNJ) Chairman William Weldon's annual base salary was reduced by nearly half to $1 million after he stepped down as chief executive last month, the company said Monday.

Weldon's previous annual base salary was set at $1.97 million for 2012, for his roles as both chairman and CEO, but with the expectation that J&J's board would consider the appropriate compensation for Weldon in his role as chairman only.

The decrease reflects that Weldon is no longer CEO, said spokesman Al Wasilewski.

On April 26, Alex Gorsky succeeded Weldon as CEO. Weldon is continuing as chairman and will remain an employee of the company, J&J said in a quarterly report filed with the Securities and Exchange Commission Monday.

J&J said in a previous SEC filing that in his role as chairman, Weldon will work closely with Gorsky to ensure a seamless leadership transition. During this time, all day-to-day management and operational responsibilities are being transferred to Gorsky.

Weldon will remain an employee but not a member of the J&J executive committee, which is the principal management group responsible for strategic operations and allocations of the resources of the company.

Weldon's main duties as chairman will include working with the board of directors, facilitating communication between the board and management, assisting Gorsky in business planning and strategy, representing the company before governmental and other organizations, and serving as chairman of the board's finance committee.

-By Peter Loftus, Dow Jones Newswires; +1-215-982-5581;

React to this article
Latest news on JOHNSON & JOHNSON
02:06a JOHNSON & JOHNSON : 6 A plan by the makers
02:00a JOHNSON & JOHNSON : A plan by the makers ; CITY DESK
05/22 JOHNSON & JOHNSON : STELARA® Receives CHMP Positive Opinion For Treatment Of Ado..
05/22 JOHNSON & JOHNSON : SIMPONI® Receives CHMP Positive Opinion For Treatment Of Non..
05/22 JOHNSON & JOHNSON : Pharmaceutical Segment to Continue Driving Above-Industry Gr..
05/22 JOHNSON & JOHNSON : UK watchdog says Reckitt's K-Y buy could hurt competition
05/22 RECKITT BENCKISER : Press release: CMA sets out provisional concerns over lubric..
05/22DJRECKITT BENCKISER : Personal Lubricants Buy May Lessen Competition -UK Regulator
05/21 JOHNSON & JOHNSON : JNJ) Closes 0.42% Down on the Day for May 21
05/21 JOHNSON & JOHNSON : Risperdal Lawyers at Bernstein Liebhard LLP Look Ahead to Ju..
Duration : Period :
Johnson & Johnson Technical Analysis Chart | JNJ | US4781601046 | 4-Traders
Income Statement Evolution
More Financials